AA
NVO

AlphaCentric Advisors’s Novo Nordisk NVO Stock Holding History

AlphaCentric Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$2.01M Buy
+23,334
New +$2.52M 2% 9

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

AlphaCentric Advisors's NVO Position: Q4 2024 in Review

AlphaCentric Advisors opened a new position in Novo Nordisk (NVO) in Q4 2024: 23,334 shares worth $2.01M. The stake represents 2% of the portfolio and ranks #9 among its holdings.

1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • AlphaCentric Advisors held 23,334 shares of Novo Nordisk worth $2.01M as of Q4 2024.
  • Novo Nordisk was a new AlphaCentric Advisors position in Q4 2024.
  • Novo Nordisk made up 2% of AlphaCentric Advisors's portfolio in Q4 2024, its #9 holding.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.